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ABSTRACT
Sirolimus is increasingly used in transplantation for prevention and treatment of graft-versus-host disease and
organ rejection. Voriconazole is contraindicated when used concomitantly with sirolimus because of a sub-
stantial increase in sirolimus drug exposure with unadjusted dosing, but voriconazole is also considered the
best initial treatment of invasive aspergillosis and other fungal infections. Patients who received voriconazole
and sirolimus concomitantly were identified by a review of the medical records of all allogeneic hematopoietic
stem cell recipients at our institution from September 1, 2002, to June 1, 2005. Data including baseline
characteristics, indications for both drugs, and potential adverse effects were evaluated. Eleven patients
received voriconazole and sirolimus concomitantly for a median of 33 days (range, 3-100 days). In 8 patients
whose sirolimus dose was initially reduced by 90%, trough sirolimus levels were similar to those obtained
before the administration of voriconazole; no obvious significant toxicity from either drug was observed during
coadministration. Serious adverse events were observed in 2 patients in whom sirolimus dosing was not
adjusted during voriconazole administration. Sirolimus and voriconazole may be safely coadministered if there
is an empiric initial 90% sirolimus dose reduction combined with systematic monitoring of trough levels.
© 2006 American Society for Blood and Marrow Transplantation
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aNTRODUCTION
Sirolimus has been increasingly used for the pre-
ention and treatment of graft-versus-host disease
GVHD) in allogeneic hematopoietic stem cell trans-
lantation (HSCT) and of organ rejection in solid
rgan transplant recipients [1-4]. Potential advantages
f sirolimus administration include synergy and few
verlapping toxicities when used in combination with
acrolimus or cyclosporine, a prolonged half-life, and
wide therapeutic window [1]. After transplantation,
hese patients are at increased risk for invasive aspergil-
osis (IA) [5,6] and other invasive fungal infections (IFIs)
7]. Voriconazole is currently considered the best initial
reatment of IA [8] and other IFIs, such as those caused
y Fusarium species and Scedosporium apiospermum [9,10].
The use of voriconazole in combination with
irolimus was contraindicated at the time of voricon- t
52zole approval because of a substantial increase in
irolimus drug exposure in healthy subjects from
oriconazole inhibition of several cytochrome P450
CYP) isoenzymes [11]. Voriconazole has been shown
o cause an 11.1-fold increase in the sirolimus peak
lasma concentration and a 6.6-fold increase in the
rea under the plasma concentration-time curve
11,12]. Thus, in patients who are receiving sirolimus
nd develop IA or other IFIs in which voriconazole is
onsidered the best treatment option, clinicians may
e faced with the difﬁcult decision of whether to
ithdraw sirolimus or choose a suboptimal antifungal
gent.
Over the past few years, several HSCT patients at
ur institution who were receiving sirolimus needed
ntifungal treatment with voriconazole. In some of
hese cases, because of the need to manage GVHD
Table 1. Demographics
Patient
No.
Age
(y) Sex
Underlying
Disease
HSCT
Source
Relation
to Donor
Days after HSCT
at Time of
Initiation of
Coadministration
SRL Indication
for GVHD VCZ Indications
VCZ Maintenance
Dose (mg/d) Clinical Syndrome
1 51 M ALL PBSC MMU 1170 Treatment Probable IA 400 Cavitary lung lesions,  culture
2 42 F AML PBSC MU 355 Treatment Probable IA 400 Lung nodules,  culture
3 33 F AA Cord MMU 16 Prophylaxis Probable IA 800 Lung nodules,  galactomannan
4 40 M CML PBSC MU 69 Prophylaxis Empiric therapy 400 Sinusitis
5 58 M AML PBSC MU 33 Treatment Empiric therapy 400 Pneumonia
6 48 M NHL PBSC MU 7 Prophylaxis Probable
fusariosis
400 Lung nodules,  culture
7 51 M CLL PBSC MU 182 Treatment Empiric therapy 600 Pneumonia
8 28 M NHL PBSC MU 190 Treatment Probable IA 600 Pneumonia,  culture
9 28 F CML Cord MMU 81 Treatment Prophylaxis 400 Previous candidemia
10 27 M AML PBSC MMU 54 Treatment Proven IA 600 Sinusitis
11 37 F CML PBSC MU 64 Treatment Empiric therapy 400 Lung nodules
AML indicates acute myelogenous leukemia; CML, chronic myelogenous leukemia; NHL, non-Hodgkin’s lymphoma; ALL, acute lymphocytic leukemia; CLL, chronic lymphocytic leukemia; AA,
aplastic anemia; PBSC, peripheral blood stem cells; Cord, umbilical cord stem cells; MMU, mismatched unrelated donor; MU, matched unrelated donor; HSCT, hematopoietic stem cell
transplantation; SRL, sirolimus; GVHD, graft-versus-host disease; VCZ, voriconazole; IA, invasive aspergillosis.
Table 2. Sirolimus and Voriconazole Dosing Regimens
Patient
No.
Days of
Coadministration
Duration of
SRL Therapy
When VCZ
Initiated
(d)
SRL Dose
before
VCZ
Start
(mg/d)
SRL Dose
Adjustment
at VCZ
Initiation
(mg/d)
Duration of
Treatment at
This Dose (d)
SRL Steady-
State Dose if
Different from
Initial Dose
Adjustment (mg/d)
SRL Level
before VCZ
Initiation
(ng/mL)
Average
Steady-State
SRL Level
(ng/mL)
No.
Levels
Measured
Lowest
SRL Level
after VCZ
Initiation
(ng/mL)
Highest
SRL Level
after VCZ
Initiation
(ng/mL)
Days on
Combination
at Highest
SRL Level
1 100 422 2 0.2 100 — 7.4 10.4 2 9.1 11.7 1
2 97 120 3 0.3 97 — 9.1 6.1 1 6.1 6.1 23
3 70 22 4 0.4 21 0.20 7.8 4.5 53 1.1 9.9 16
4 42 72 2 2.0* 6 0.20 4.5 10.0 4 1.5 29.6 6
5 40 36 4 0.4 40 — 8.2 8.8 13 2.8 13.9 40
6 19 10 4 0.4 13 — 5.9 3.9 17 2.2 6.0 2
7 8 185 4 0.4 8 — 4.0 2.3 6 1.3 3.2 0
8 8 193 4 0.0† 3 0.40 <1.5‡ 3.5 7 3.0 4.6 8
9 3 84 1 0.1 3 — 2.5 1.9 1 1.9 1.9 3
10 33 57 3 3.0 12 2.60 4.0 19.2 2 15.0 23.4 5
11 7 19 3 3.0 7 — 9.1 18.9 3 15.3 23.5 8
SRL indicates sirolimus; VCZ, voriconazole.
*Voriconazole was initiated by the local health care provider at presentation with sinusitis and adjusted 6 days later during a clinic visit.
†Sirolimus was discontinued on the day voriconazole was started but was restarted at-lower dose 3 days later.
‡Limit of detection of the assay.
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5nd the IFI, it was judged to be in the patient’s best
nterest to coadminister both medications. An empiric
ose reduction in sirolimus was made, in most cases,
n the basis of the projected increase in sirolimus levels
rom voriconazole coadministration. We present a series
f all patients treated at our institution in whom both
rugs were coadministered and report the feasibility and
afety of such an approach.
ETHODS
The Partners Healthcare System Human Re-
earch Committee approved this study. A retrospec-
ive medical record review of all HSCT recipients in
hom voriconazole and sirolimus were coadminis-
ered between September 1, 2002 (when voriconazole
ecame available at our institution), and June 1, 2005,
as performed. Patients were identiﬁed by using com-
uterized inpatient and outpatient medication-dis-
ensing records. Information regarding patient age at
he time of coadministration, sex, underlying hemato-
ogic disease, donor relatedness, voriconazole and
irolimus indications for use, drug dose and dosage
djustments, concomitant tacrolimus use, drug levels,
se of nephrotoxic medications, need for dialysis, ad-
erse events, vital status, and cause of death was col-
ected from the medical record. Trough tacrolimus
nd sirolimus levels were routinely obtained for clinical
anagement at the discretion of the treating clinicians.
Coadministration was deﬁned as the administra-
ion of both voriconazole and sirolimus for 1 day.
he sirolimus dose and duration of therapy before
he initiation of voriconazole were captured and
ompared with the dose of sirolimus at the time of
able 3. Renal Adverse Effects
Patient
No.
Serum Creatinine
at VCZ Initiation
(mg/dL)
Peak Serum
Creatinine on
Combination
(mg/dL)
Days
at
Crea
1 0.8 1.0
2 1.0 1.0
3 0.5 1.2
4 1.1 1.4
5 1.1 1.9
6 2.1 5.9
7 1.4 4.0†
8 1.8 3.4
9 0.5 0.5
10 1.9 3.3§
11 0.8 2.0
CZ indicates voriconazole; TAC, tacrolimus; L-AmB, liposomal
Reason for dialysis: acute tubular necrosis was attributed to L-Am
Attributed to tacrolimus toxicity.
Reason for dialysis: hepatorenal syndrome secondary to veno-occ
Attributed to septic shock and probable tacrolimus toxicity.
Attributed to tacrolimus toxicity.oriconazole initiation and the steady-state dose of f
54irolimus during coadministration. Sirolimus
rough levels immediately preceding voriconazole
nitiation, the highest measured sirolimus trough
evel, and the average sirolimus trough level at
teady state during coadministration were deter-
ined. These parameters were also captured for
acrolimus if it was used concomitantly with siroli-
us and voriconazole.
The indication for sirolimus use was categorized
s either treatment of or prophylaxis against GVHD.
he indication for voriconazole administration was
ategorized as treatment of proven or probable IFI on
he basis of current diagnostic criteria [13], empiric
herapy, or prophylaxis. Potential voriconazole and
irolimus adverse drug events were recorded. Baseline,
eak, and coadministration measurements were re-
orded for creatinine, aspartate aminotransferase (AST),
lanine aminotransferase (ALT), alkaline phosphatase,
holesterol, triglyceride, and corrected QT inter-
als (QTc).
Acute renal failure was deﬁned as a serum creati-
ine level 2 mg/dL or a 50% increase in serum
reatinine from baseline. Concomitant use of the fol-
owing potentially nephrotoxic medications was re-
orded: amphotericin B products, iodinated intrave-
ous contrast agents, aminoglycosides, cyclosporine,
nd foscarnet. AST, ALT, or alkaline phosphatase
easurements in excess of 3 times the upper limit of
ormal were considered clinically signiﬁcant. For pa-
ients who died during the study period, conditions
resent at the time of death were established from
utopsy reports or physician notes. Two-tailed Fisher
xact tests or Wilcoxon tests were used as appropriate
Serum Creatinine
at VCZ end
(mg/dL)
Concomitant
Use of TAC
(d)
TAC Dose
before VCZ
Initiation
(mg/d)
0.9 0 1
0.9 0 —
0.8 70 4
0.8 42 2
1.5 40 1
2.3 19 1.5 (IV)
4.0 8 5
3.4 0 —
0.5 3 6
3.3 33 3 (PO)
2.0 7 0.5
ericin B; IV, intravenous; PO, oral.
isease of the liver.on VCZ
Peak
tinine
9
23
20
7
45
4
8
8
1
32
9
amphot
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BESULTS
Twenty-ﬁve HSCT patients receiving sirolimus
ere prescribed voriconazole between September 1,
002, and June 1, 2005. In 14 patients, sirolimus was
iscontinued at the time of initiation of voriconazole.
hese patients are not considered further.
Eleven patients received voriconazole and siroli-
us concomitantly during the study period. The base-
ine characteristics of these patients are presented in
able 1. The median patient age was 40 years (range,
7-58 years). Seven of the 11 patients were male.
nderlying hematologic malignancies were acute my-
logenous leukemia (3 patients), chronic myelogenous
eukemia (3 patients), non-Hodgkins lymphoma (2
atients), and acute lymphoblastic leukemia, aplastic
nemia, and chronic lymphocytic leukemia (1 patient
ach). Nine of the 11 patients received peripheral stem
ells, and 2 patients received umbilical cord blood
tem cells. The median time from transplantation to
oriconazole-sirolimus coadministration was 69 days
range, 7-1170 days). Eight of the 11 patients received
irolimus for treatment of GVHD, and 3 received
irolimus for GVHD prophylaxis. Five patients re-
eived voriconazole for proven or probable IA, 4 pa-
ients for empiric therapy, 1 patient for probable fusa-
iosis, and 1 patient for antifungal prophylaxis.
All patients received sirolimus before starting vori-
onazole. Sirolimus and voriconazole were coadmin-
stered for a median of 33 days (range, 3-100 days;
able 2), for a total of 427 patient-days of observation.
he median duration of sirolimus therapy before vori-
onazole initiation was 72 days (range, 10-422 days).
atients received a stable daily dose of sirolimus for a
able 3. Continued
TAC Dose
Adjustment at
VCZ Initiation
(mg/d)
TAC Steady-State Dose if
Different from Initial
Dose Adjustment
(mg/d)
TAC L
before
Initiat
(ng/m
— — 6.2
— — —
2.0 0.5 6.6
2.0 1.0 2.4
0.5 1.0 7.7
1.5 (IV) 2.0 (PO) 5.9
6.0 — 4.7
— — —
3.0 2.0 2.6
0.7 (IV) 1.0 (PO) 5.4
0.5 — 2.8edian of 12 days (range, 1-50 days) before voricon- r
B&MTzole was added. The median voriconazole mainte-
ance dose was 400 mg/d (range, 400-800 mg/d).
Eight of 11 patients had their sirolimus reduced to
0% of the stable daily dose at the time voriconazole
as initiated. Sirolimus solution (Rapamune 1 mg/
L; Wyeth Pharmaceuticals Inc., Philadelphia, PA)
as used for ease of administration of the reduced
osage. Sirolimus was usually ingested with the rest of
he patient’s morning medications, which included
oriconazole. No patient with an empiric 90% dose
eduction had a plasma sirolimus level above the ther-
peutic target trough range (3-12 ng/mL) [1] during
oadministration, except for a single level of 13.9
g/mL in patient 5 which occurred on day 40 of
oncomitant use. For these patients, the median aver-
ge steady-state trough level on the combination was
.2 ng/mL (range, 1.9-10.4 ng/mL), which was not
ifferent from pretreatment levels (P  .72; Table 2).
he median highest sirolimus trough level was 6.1
g/mL (range, 1.9-13.9 ng/mL), which occurred a
edian of 6 days (range, 0-40 days) after the initiation
f voriconazole administration and was not signiﬁcantly
ifferent from previous levels (P  .57). The median
umber of levels measured was 6.5 (range, 1-53).
Three patients did not have an empiric sirolimus
osage reduction at the time voriconazole was initi-
ted. In patient 4, a local health provider prescribed
oriconazole for empiric treatment of sinusitis, but the
irolimus dose was reduced to 10% 6 days later when
e was seen in our clinic. All patients without an
mpiric 90% sirolimus dosage adjustment at the time
f voriconazole initiation (patients 4, 10, and 11) had
irolimus levels that exceeded the target therapeutic
Highest TAC
after VCZ
Initiation
(ng/mL)
Concomitant Use
of Nephrotoxic
Medication
Required
Dialysis
— L-AmB No
— — No
16.8 L-AmB, foscarnet No
7.5 — No
6.2 L-AmB No
13.7 L-AmB Yes*
24.5 L-AmB, foscarnet No
— — Yes‡
21.8 IV contrast No
15.8 — No
24.4 L-AmB Noevel
VCZ
ion
L)ange. The median average steady-state sirolimus
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5evel on the combination was 18.9 ng/mL (range,
0.0-19.2 ng/mL), and the median peak sirolimus
evel was 23.5 ng/mL (range, 23.4-29.6 ng/mL). The
edian number of levels measured was 3 (range, 2-4).
Eight patients received tacrolimus [4] in addition
o voriconazole and sirolimus (Table 3). In 4 of these
atients, there was an empiric 50% tacrolimus dose
eduction at the time of voriconazole initiation. Ta-
rolimus trough concentrations exceeded the thera-
eutic range in 1 of these patients 3 days after initia-
ion of voriconazole. Of the 4 patients with no
acrolimus dose adjustment at the time of voricon-
zole initiation, 2 patients had trough concentrations
bove the target therapeutic range. Patient 11 devel-
ped thrombotic microangiopathy (TMA) [14,15] and
evere posterior leukoencephalopathy attributed to ta-
rolimus toxicity. The patient later died of a subarach-
oid hemorrhage.
In 5 of 11 patients, serum creatinine at the end of
able 4. Adverse Effects Potentially Associated with Voriconazole and S
Patient
No.
Baseline
QTc
(ms)
Peak QTc
on SRL 
VCZ (ms)
Baseline
AST
(IU/L)
P
S
1 411 — 36
2 410 456 28
3 414 459 31
4 418 — 78
5 404 450 153
6 416 —* 13
7 478 471 19
8† 447 — 99
9 428 — 23
10 401 399 19
11 440 452 45
Tc indicates corrected QT interval; SRL, sirolimus; VCZ, vorico
AlkPhos, alkaline phosphatase.
Voriconazole was discontinued due to bradycardia attributed to th
Patient had hepatorenal syndrome secondary to veno-occlusive di
able 5. Outcomes and Death-Related Data
Patient
Vital
Status*
Days after HSCT
at Time of Death
or 6/1/05
On SRL  VCZ at
Time of Death or
6/1/05
1 Alive 1593 No
2 Alive 894 No
3 Alive 86 Yes
4 Alive 111 Yes
5 Dead 82 No
6 Alive 614 No
7 Dead 190 Yes
8 Dead 198 Yes
9 Dead 202 No
10 Dead 88 Yes
11 Dead 92 No
SCT indicates hematopoietic stem cell transplantation; DAD/AR
cytomegalovirus; VOD, veno-occlusive disease; MRSA, methi
SRL, sirolimus; VCZ, voriconazole; NOS, not otherwise speciﬁAs of June 1, 2005 (end of study period).
56oriconazole-sirolimus coadministration was similar
o baseline levels (Table 3), without evidence of acute
enal dysfunction. Five patients developed acute renal
ailure, which was transient in 1 patient who was
eceiving liposomal amphotericin B and foscarnet.
wo patients required dialysis; patient 8 had hepato-
enal syndrome due to veno-occlusive disease of the
iver, and patient 6 developed acute tubular necrosis
uring treatment with liposomal amphotericin B be-
ore voriconazole was initiated. When patients were
nalyzed as a group, we could not demonstrate an
ssociation between tacrolimus or liposomal ampho-
ericin B use and acute renal failure (P  1; Table 3).
Adverse effects associated with voriconazole use
ere uncommon (Table 4). Four of the 11 patients
ad peak increases of AST, ALT, or alkaline phospha-
ase 3 times the upper limit of normal (30, 52, and
18 U/L, respectively, at our institution) during co-
dministration. Patient 8 had veno-occlusive disease
s
T on
CZ
)
AST after VCZ
Discontinued
(IU/L)
Baseline
ALT
(IU/L)
Peak ALT on
SRL  VCZ
(IU/L)
— 34 40
27 29 120
12 59 65
32 103 46
18 116 96
23 20 35
25 19 20
94 101 115
36 30 49
— 17 33
492 85 325
; AST, aspartate aminotransferase; ALT, alanine aminotransferase;
.
f the liver.
utopsy Conditions Present at Time of Death
— —
— —
— —
— —
Yes DAD/ARDS, enterococcal bacteremia (postmortem)
— —
No CMV colitis, probable staphylococcal pneumonia
Yes Hepatorenal syndrome, DAD, VOD
No Pneumonia
Yes MRSA bacteremia/sepsis, pulmonary syndrome NOS
No Tacrolimus toxicity/TMA
iffuse alveolar damage/acute respiratory distress syndrome; CMV,
sistant Staphylococcus aureus; TMA, thrombotic microangiopathy;irolimu
eak AS
RL  V
(IU/L
44
72
36
37
114
29
33
156
28
266
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Bf the liver; in patient 5, peak AST, ALT, and alkaline
hosphatase levels occurred before the initiation of
oriconazole. Voriconazole was discontinued in pa-
ient 6, who developed bradycardia without QTc pro-
ongation during treatment. QTc prolongation com-
ared with baseline was not observed in the 6 patients
ho had measurements during coadministration.
nly patient 3 had trough voriconazole levels mea-
ured during the study period. Voriconazole levels
anged between 2.6 and 4.3 ng/mL (n  4) on an oral
ose of 800 mg/d; she experienced no voriconazole-
elated toxicity.
Serum cholesterol and triglycerides were infre-
uently measured during voriconazole-sirolimus co-
dministration (Table 4). Cholesterol levels were
easured in 3 patients during coadministration and
ere similar to baseline levels. Triglycerides were
easured in 4 patients at baseline and during coad-
inistration. In 2 patients, the triglyceride level dur-
ng coadministration was 2 to 3 times higher than the
aseline level. In 1 patient there was a 50% reduction
n the triglyceride level during coadministration, and
n another patient the triglyceride levels remained
nchanged.
At the end of the study period, 6 patients had died
Table 5), 3 of whom were receiving both sirolimus
nd voriconazole at the time of death. Autopsies were
erformed in 3 patients (50%). Two patients in whom
he sirolimus and tacrolimus doses were not adjusted
ied. Death was attributed to tacrolimus-associated
MA complicated by posterior leukoencephalopathy
nd subarachnoid hemorrhage in patient 11. Patient
0 died from complications of catheter-related methi-
illin-resistant Staphylococcus aureus (MRSA) sepsis and
oagulopathy. At autopsy, his lungs exhibited multi-
ocal consolidation on gross examination that was in-
erpreted as consistent with a panlobular broncho-
able 4. Continued
ALT after VCZ
Discontinued
(IU/L)
Baseline
AlkPhos
(IU/L)
Peak
AlkPhos
(IU/L)
AlkPhos after VCZ
Discontinued (IU/
L)
— 84 136 —
26 91 174 96
12 53 239 133
39 141 99 93
24 374 325 191
33 114 116 86
10 100 122 97
64 592 586 523
49 284 331 330
— 99 286 —
277 62 210 173neumonia, but microscopic examination revealed v
B&MTiffuse mild ﬁbrinous exudates, diffuse (but patchy)
cute alveolar hemorrhage, and bronchial mucus plug-
ing. Three patients died from bacterial or viral in-
ectious complications, and 1 patient died from veno-
cclusive disease of the liver with hepatorenal
yndrome (Table 5). No patient died of IFI.
ISCUSSION
We report the coadministration of sirolimus and
oriconazole in HSCT recipients in whom a strategy
f 90% sirolimus dose reduction at the time of initi-
tion of voriconazole was safe and well tolerated. The
mpiric dose reduction was based on changes in the
irolimus area under the plasma concentration-time
urve and peak plasma concentration observed in
ealthy volunteers with coadministration of vori-
onazole [12]. Empirically reducing the sirolimus
ose to 10% during concomitant voriconazole ad-
inistration kept sirolimus levels near prevoricon-
zole levels.
There was no obvious increase in adverse effects
ith either sirolimus or voriconazole during coadmin-
stration for patients with an empiric 90% sirolimus
eduction. The regimen was well tolerated for up to
00 days, and most patients received30 days of both
edications.
To date, there is only 1 well-documented report of
irolimus-voriconazole coadministration in 2 renal al-
ograft recipients. Sirolimus dose reductions of 75%
o 87.5% were required to achieve target concentra-
ions [16]. However, in both of these cases, the dose
eduction was made after coadministration in response
o increased sirolimus levels. The overall reduction
equired was then determined by comparing the pre-
oriconazole dose with the sirolimus dose that pro-
uced levels within the target range. No serious ad-
ine
terol
L)
Peak Cholesterol
on SRL  VCZ
(mg/dL)
Baseline
Triglycerides
(mg/dL)
Peak Triglycerides
on SRL  VCZ
(mg/dL)
— 244 —
247 312 165
215 190 463
— 200 —
— 96 —
205 170 655
— 157 208
— 498 —
— 152 —
— 504 —
— 132 —Basel
Choles
(mg/d
349
120
217
134
118
184
104
186
84
157
209erse effects were noted during coadministration.
557
t
M
l
r
o
t
a
t
f
a
d
o
[
e
c
p
M
d
a
T
i
d
i
i
t
t
a
t
r
o
t
f
t
a
i
e
h
s
t
s
a
d
d
r
s
s
d
e
q
d
i
o
p
c
A
t
b
n
R
1
1
1
1
1
F. M. Marty et al.
5In 1 patient without empiric sirolimus dose reduc-
ion in our series, whose death was attributed to
RSA bacteremia with septic embolization to the
ungs, an unusual pattern of diffuse alveolar hemor-
hage was found at autopsy. There are several reports
f sirolimus-associated lung injury in solid organ
ransplant recipients [17-20]. Most cases have been
ssociated with a syndrome of interstitial pneumonitis
hat resolved with the withdrawal of sirolimus. In the
ew cases in which lung biopsies were performed [17],
spectrum of ﬁndings have been described, including
iffuse alveolar damage, bronchiolitis obliterans with
rganizing pneumonia, and pulmonary hemorrhage
21]; no clear association with increased sirolimus lev-
ls has been made. Whether increased sirolimus levels
ontributed to the pulmonary ﬁndings in our patient is
ossible but hard to prove given the synchronous
RSA bacteremia and septic emboli.
In our series, 4 patients did not have any tacrolimus
ose adjustment at the time of voriconazole initiation,
nd 1 of these patients had severe tacrolimus-associated
MA. The interaction between azoles and calcineurin
nhibitors is well documented [22,23]. All systemic azole
rugs currently used in transplantation (ﬂuconazole,
traconazole, and voriconazole) inhibit several CYP
soenzymes, especially CYP3A4, which is the main sys-
em used for cyclosporine and tacrolimus metabolism,
hus reliably increasing their levels. Calcineurin dose
djustments must always be considered when antifungal
herapy is initiated and discontinued, to minimize the
isk of calcineurin toxicity or the development of GVHD
r organ rejection. Initial reductions to at least one third
o one half of the preazole administration dose and
requent drug level measurements during the antifungal
ransition periods (both at initiation and discontinuation)
re recommended [24].
In addition, azole antifungal drugs are known to
nhibit intestinal P-glycoprotein [25], which may
nhance the oral bioavailability of calcineurin in-
ibitors [25] and sirolimus [26]. The patients in this
eries received sirolimus and voriconazole together
o facilitate patient adherence. The effect of non-
ynchronous administration of these drugs on the
bsorption and levels of sirolimus has not been
escribed but could potentially lead to an empiric
ose adjustment of sirolimus different from the 90%
eduction reported.
Although this experience is relatively small, it
upports that sirolimus and voriconazole can be
afely coadministered with an appropriate sirolimus
ose reduction and drug level monitoring. An initial
mpiric 90% sirolimus dose reduction seems ade-
uate, but more frequent sirolimus trough level
eterminations should be performed at the time of
nitiation of voriconazole. A prospective evaluation
f this strategy should be conducted to conﬁrm that
58atients may receive both medications safely when
linically required.
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